IL6 and juvenile idiopathic arthritis: Recent studies have shown that pharmacological blockade of IL-6 by a humanized anti-IL-6 receptor antibody is beneficial in patients with rheumatoid arthritis and JIA, suggesting that IL-6 might be an essential key cytokine in these diseases.